tetano
Editor, Senior Moderator
J Clin Med
. 2021 Dec 19;10(24):5960.
doi: 10.3390/jcm10245960.
Uveitis and Other Ocular Complications Following COVID-19 Vaccination
Elena Bolletta[SUP] 1 [/SUP], Danilo Iannetta[SUP] 2 [/SUP], Valentina Mastrofilippo[SUP] 1 [/SUP], Luca De Simone[SUP] 1 [/SUP], Fabrizio Gozzi[SUP] 1 [/SUP], Stefania Croci[SUP] 3 [/SUP], Martina Bonacini[SUP] 3 [/SUP], Lucia Belloni[SUP] 3 [/SUP], Alessandro Zerbini[SUP] 3 [/SUP], Chantal Adani[SUP] 1 [/SUP], Luigi Fontana[SUP] 4 [/SUP], Carlo Salvarani[SUP] 5 6 [/SUP], Luca Cimino[SUP] 1 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18-83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet's disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1-30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine.
Keywords: COVID-19; SARS-CoV-2 disease; ocular complications; uveitis; vaccination; vaccine; vaccine-associated uveitis.
. 2021 Dec 19;10(24):5960.
doi: 10.3390/jcm10245960.
Uveitis and Other Ocular Complications Following COVID-19 Vaccination
Elena Bolletta[SUP] 1 [/SUP], Danilo Iannetta[SUP] 2 [/SUP], Valentina Mastrofilippo[SUP] 1 [/SUP], Luca De Simone[SUP] 1 [/SUP], Fabrizio Gozzi[SUP] 1 [/SUP], Stefania Croci[SUP] 3 [/SUP], Martina Bonacini[SUP] 3 [/SUP], Lucia Belloni[SUP] 3 [/SUP], Alessandro Zerbini[SUP] 3 [/SUP], Chantal Adani[SUP] 1 [/SUP], Luigi Fontana[SUP] 4 [/SUP], Carlo Salvarani[SUP] 5 6 [/SUP], Luca Cimino[SUP] 1 6 [/SUP]
Affiliations
- PMID: 34945256
- DOI: 10.3390/jcm10245960
Abstract
Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18-83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet's disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1-30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine.
Keywords: COVID-19; SARS-CoV-2 disease; ocular complications; uveitis; vaccination; vaccine; vaccine-associated uveitis.